Blog

Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24

Photo from Giuseppe Curigliano/X

Jun 5, 2024, 05:51

Francisco J. Esteva: Congratulations to Giuseppe Curigliano for the presentation of the DESTINY-Breast06 trial at ASCO24

Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: .

“Congratulations to Giuseppe Curigliano for the outstanding presentation of the DESTINY-Breast06 trial at the ASCO Annual Meeting.

The improvement in progression-free survival in the group of patients treated with trastuzumab deruxtecan (T-DXd, Enhertu) compared to conventional chemotherapy is statistically significant and clinically meaningful.

Practice changing study!”

No alternative text description for this image

Source: Francisco J. Esteva/LinkedIn

ASCO ASCO24 cancer conventional chemotherapy DESTINY-Breast06 Trial Enhertu Francisco J. Esteva Giuseppe Curigliano Lenox Hill Hospital OncoDaily Oncology T-Dxd Trastuzumab deruxtecan

Melanie Griffith and Skin Cancer: How She Went Against, How She Survived, and More

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Gemma Peters: Heading into 2025 with hope

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Special Coverage